TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings estimates for shares of TScan Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.23) per share for the quarter. Wedbush has a "Outperform" rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS and Q4 2026 earnings at ($0.22) EPS.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.
TCRX has been the topic of a number of other reports. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays dropped their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Finally, HC Wainwright dropped their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $8.50.
Check Out Our Latest Stock Analysis on TCRX
TScan Therapeutics Stock Up 2.6 %
Shares of TCRX stock opened at $1.40 on Thursday. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69. The stock has a market cap of $78.94 million, a P/E ratio of -1.32 and a beta of 1.06. The stock has a 50 day moving average of $1.52 and a 200 day moving average of $2.78. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.
Institutional Trading of TScan Therapeutics
Institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its holdings in TScan Therapeutics by 341.1% in the 3rd quarter. Barclays PLC now owns 58,067 shares of the company's stock valued at $289,000 after purchasing an additional 44,903 shares in the last quarter. JPMorgan Chase & Co. boosted its position in TScan Therapeutics by 94.4% during the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company's stock worth $158,000 after acquiring an additional 15,441 shares during the last quarter. SG Americas Securities LLC grew its stake in TScan Therapeutics by 31.2% during the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock valued at $62,000 after acquiring an additional 4,852 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in TScan Therapeutics in the 4th quarter valued at about $61,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in TScan Therapeutics in the 4th quarter worth approximately $32,000. 82.83% of the stock is owned by institutional investors and hedge funds.
About TScan Therapeutics
(
Get Free Report)
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
